<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="t0010">
 <label>Table 2</label>
 <caption>
  <p>COVID-19 vaccine candidates currently enrolled in active clinical trials.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Name</th>
    <th>Platform</th>
    <th>Allocation &amp; Masking</th>
    <th>Developer</th>
    <th>Clinical Trial Status</th>
    <th>Strength</th>
    <th>Trial Location</th>
    <th>Estimated Date of Completion</th>
    <th>References</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>
     <bold>mRNA 1273</bold>
    </td>
    <td>Lipid nanoparticle encapsulated mRNA vaccine encoding S protein.</td>
    <td>Randomized; Double blind</td>
    <td>Moderna/National Institute Of Allergy And Infectious Diseases (NIAID)</td>
    <td>Phase II trial (NCT04405076)</td>
    <td>600</td>
    <td>United States</td>
    <td>August 2021</td>
    <td rowspan="8">
     <xref rid="b0415" ref-type="bibr">[83]</xref>, 
     <xref rid="b0420" ref-type="bibr">[84]</xref>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Lentiviral Minigene Vaccines (LV-SMENP-DC</bold>)
    </td>
    <td>Lentiviral vector system (NHP/TYF) used to modify dendritic cells (DCs) and to activate T cells.</td>
    <td>Non-Randomized; Open Label</td>
    <td>Shenzhen Geno-Immune Medical Institute</td>
    <td>Phase I (NCT04276896)</td>
    <td>100</td>
    <td>Shenzen, China</td>
    <td>December 31, 2024</td>
   </tr>
   <tr>
    <td>
     <bold>Bacillus Calmette-Guerin (BCG) live-attenuated vaccine*</bold>
    </td>
    <td>Live-attenuated vaccine that induces a broad immune-system response.</td>
    <td>Randomized; Open Label
     <break/>AND
     <break/>Randomized; Quadruple
    </td>
    <td>Murdoch Children's Research Institute;
     <break/>And
     <break/>UMC Utrecht
    </td>
    <td>Phase III BRACE trial - (NCT04327206)
     <break/>AND
     <break/>Phase III BCG-CORONA trial - (NCT04328441)
    </td>
    <td>4,170 (Australia)
     <break/>AND
     <break/>1500 (Netherlands)
    </td>
    <td>Australia
     <break/>AND
     <break/>The Netherlands
    </td>
    <td>March 30, 2022
     <break/>AND
     <break/>December 25, 2020
    </td>
   </tr>
   <tr>
    <td>
     <bold>INO-4800</bold>
    </td>
    <td>DNA plasmid vaccine.</td>
    <td>Non-Randomized; Open Label</td>
    <td>Inovio Pharmaceuticals
     <break/>AND
     <break/>Coalition For Epidemic Preparedness Innovations (CEPI)
    </td>
    <td>Phase I (NCT04336410)</td>
    <td>40</td>
    <td>Philadelphia and Kansas City, USA</td>
    <td>April 2021</td>
   </tr>
   <tr>
    <td>
     <bold>AD5-nCov</bold>
    </td>
    <td>Recombinant non-replicating viral vector vaccine. (adenovirus type 5 vector)</td>
    <td>Non-Randomized; Open Label</td>
    <td>Cansino Biological Inc./Beijing Institute of Biotechnology</td>
    <td>Phase I trial (NCT04313127)
     <break/>AND
     <break/>Randomized controlled phase II trial (ChiCTR2000031781)
    </td>
    <td>108
     <break/>AND
     <break/>500
    </td>
    <td>Wuhan, Hubei, China</td>
    <td>December 20, 2022 (Phase 1)
     <break/>AND
     <break/>January 2021 (Phase 2)
    </td>
   </tr>
   <tr>
    <td>
     <bold>AZD1222 (PreviouslyChAdOx1 nCoV-19)</bold>
    </td>
    <td>Non-replicating chimpanzee adenovirus vector.</td>
    <td>Randomized; Single blinded</td>
    <td>University Of Oxford</td>
    <td>Phase II/III trial (NCT04400838)</td>
    <td>10,260</td>
    <td>United Kingdom</td>
    <td>August 2021</td>
   </tr>
   <tr>
    <td>
     <bold>Pathogen-specific aAPC</bold>
    </td>
    <td>aAPCs modified with lentiviral vector expressing synthetic minigenes.</td>
    <td>Non-Randomized; Open Label</td>
    <td>Shenzhen Geno-Immune Medical Institute</td>
    <td>Phase I (NCT04299724)</td>
    <td>100</td>
    <td>Shenzen, China</td>
    <td>December 31, 2024</td>
   </tr>
   <tr>
    <td>
     <bold>CoronaVac (Previously PiCoVacc)</bold>
    </td>
    <td>Formalin-Inactivated + alum adjuvant</td>
    <td>Randomized; Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</td>
    <td>Sinovac</td>
    <td>Phase I (NCT04352608)
     <break/>AND
     <break/>Phase II (NCT04383574).
    </td>
    <td>143
     <break/>AND
     <break/>600
    </td>
    <td>Jiangsu, China</td>
    <td>December 13, 2020</td>
   </tr>
   <tr>
    <td>
     <bold>BNT162</bold>
    </td>
    <td>Four mRNA vaccines: 2 nucleoside modified mRNA-based (modRNA), 1 uridine containing mRNA-based (uRNA), and 1 self-amplifying mRNA-based (saRNA).</td>
    <td>Non-Randomized; Open Label</td>
    <td>Pfizer and BioNtech</td>
    <td>Phase I/II (NCT04380701)</td>
    <td>200</td>
    <td>Berlin, Germany</td>
    <td>August 2020</td>
    <td/>
   </tr>
   <tr>
    <td>
     <bold>Inactivated Vaccine</bold>
    </td>
    <td>Inactivated Novel Coronavirus Pneumonia vaccine (Vero cells)</td>
    <td>Randomized; Double blind</td>
    <td>Wuhan Institute of Biological Products
     <break/>AND
     <break/>China National Pharmaceutical Group (Sinopharm)
    </td>
    <td>Phase I/II (ChiCTR2000031809)</td>
    <td>1456</td>
    <td>Wuhan, China</td>
    <td>November 2021</td>
    <td/>
   </tr>
   <tr>
    <td>
     <bold>BBIBP-CorV</bold>
    </td>
    <td>Inactivated novel coronavirus (2019-CoV) vaccine (Vero cells)</td>
    <td>Randomized; Double blind</td>
    <td>Beijing Institute of Biological Products
     <break/>AND
     <break/>China National Pharmaceutical Group (Sinopharm)
    </td>
    <td>Phase II (ChiCTR2000032459)</td>
    <td>2128</td>
    <td>China</td>
    <td>November 2021</td>
    <td/>
   </tr>
   <tr>
    <td>
     <bold>GX-19</bold>
    </td>
    <td>COVID-19 Preventive DNA Vaccine</td>
    <td>Randomized; Double blind</td>
    <td>Genexine</td>
    <td>Phase I/IIa (NCT04445389)</td>
    <td>190</td>
    <td>Seoul, Republic of Korea</td>
    <td>March 2021</td>
    <td/>
   </tr>
   <tr>
    <td>
     <bold>Gam-COVID-Vac</bold>
    </td>
    <td>Non-replicating viral vector COVID-19 vaccine candidate</td>
    <td>Non-Randomized; Open Label</td>
    <td>Gamaleya Research Institute,
     <break/>AND
     <break/>Acellena Contract Drug Research and Development
    </td>
    <td>Phase I (NCT04436471)</td>
    <td>38</td>
    <td>Moscow, Russia</td>
    <td>August 2020</td>
    <td/>
   </tr>
   <tr>
    <td>
     <bold>mRNA-based vaccine SCB-2019</bold>
    </td>
    <td>Non-chemically modified nucleotides within mRNA for activation of the immune system</td>
    <td>TBD
     <sup>**</sup>
    </td>
    <td>CureVac
     <break/>AND
     <break/>German federal government
    </td>
    <td>Phase I (Yet to commence)</td>
    <td>168</td>
    <td>Germany and Belgium</td>
    <td>TBD
     <sup>**</sup>
    </td>
    <td/>
   </tr>
   <tr>
    <td>
     <bold>SCB-2019</bold>
    </td>
    <td>COVID-19 vaccine candidate that uses Clover's S-Trimer platform, GSK's AS03 adjuvant, and Dynavax's CpG 1018 adjuvant with potassium aluminum sulfate (Alum)</td>
    <td>Randomized; Triple blind</td>
    <td>GlaxoSmithKline, Sanofi, Clover Biopharmaceuticals, Dynavax and Xiamen Innovax</td>
    <td>Phase I (NCT04405908)</td>
    <td>150</td>
    <td>Australia</td>
    <td>March 2021</td>
    <td/>
   </tr>
   <tr>
    <td>
     <bold>COVAX-19</bold>
    </td>
    <td>Monovalent recombinant protein vaccine</td>
    <td>Randomized; Triple blind</td>
    <td>Vaxine Pty Ltd.</td>
    <td>Phase I (NCT04453852)</td>
    <td>40</td>
    <td>Adelaide, Australia</td>
    <td>July 2021</td>
    <td/>
   </tr>
   <tr>
    <td>
     <bold>bacTRL-Spike</bold>
    </td>
    <td>Bifidobacteria monovalent SARS-CoV-2 DNA oral vaccine candidate</td>
    <td>Randomized; Triple blind</td>
    <td>Symvivo</td>
    <td>Phase I (NCT04334980)</td>
    <td>112</td>
    <td>Canada and United States</td>
    <td>December 2021</td>
    <td/>
   </tr>
   <tr>
    <td>
     <bold>Covaxin (BBV152)</bold>
    </td>
    <td>Inactivated whole-virion vaccine</td>
    <td>Randomized; Triple blind</td>
    <td>Bharat Biotech
     <break/>AND
     <break/>National Institute of Virology
    </td>
    <td>Phase I/II (NCT04471519)</td>
    <td>1125</td>
    <td>India</td>
    <td>June 2021</td>
    <td/>
   </tr>
   <tr>
    <td>
     <bold>ZyCoV-D</bold>
    </td>
    <td>DNA-plasmid based vaccine</td>
    <td>TBD
     <sup>**</sup>
    </td>
    <td>Zydus Cadila</td>
    <td>Phase I/II (Yet to commence)</td>
    <td>1048</td>
    <td>India</td>
    <td>2021</td>
    <td/>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="sp0045">
   <p>*- Repurposed Vaccine; Original indication: Tuberculosis (TB) pediatric vaccine **- To-be-declared.</p>
  </fn>
  <fn id="sp0050">
   <p>This table gives an overview of the global COVID-19 vaccine landscape.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
